Trendlines says its most valuable portfolio company is Stimatix
Stimatix sold its assets in Nov 2014 to a B Braun subsidiary; Trendlines' current holding of 28.2% valued at US$42.6m
Singapore
CATALIST-LISTED The Trendlines Group - an Israel and Singapore-based incubator of medtech and agritech startups - has disclosed that an asset it described as its "Most Valuable Portfolio Company" is Stimatix GI.
In a statement on Monday, Trendlines said that Stimatix, which develops medical products to aid patients with intestinal blockage, sold its assets in November 2014 to a subsidiary of German medical device company B Braun Group. B Braun will market Stimatix's ostomy products internationally from mid-2018.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Cordlife directors offer differing views on future oversight if board is rejigged
Tesla lays off more staff in software, service teams, Electrek reports
Robinhood Crypto gets Wells notice from US SEC
Morgan Stanley strategists see inflation as key for path of US stocks
US: Wall Street opens higher as rate-cut hopes linger
Tyson raises outlook as lower costs boost chicken segment